脑苷肌肽对脑出血应用的临床疗效观察.doc

《脑苷肌肽对脑出血应用的临床疗效观察.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、脑井肌肽対脑出血应用的临床疗效观察【关键词】，脑背肌肽【摘要】目的探索脑廿肌肽注射液在急性脑出血病人早期应用对•病情预后和神经功能恢复的影响。方法观察56例高血压急性脑出血病人，随机分为治疗纽和对照纽.各28例；两组常规治疗相同，治疗组早期应用脑甘肌肽注射液以APACHEII评分标准和格拉斯哥昏迷最农(GlascowcomascaleGCS)评定脑损伤程度。结果两组治疗前病情危重程度、昏迷程度无纽间差异(P>0.05)；两组治疗后APACHEII评分和GCS评分有纽间差异(P<0.05)；两组治疗前后二项评分分别有差异(

2、PV0.05)。治疗纽病例病情稳定和减轻所需时间较对照组要短，同时各种并发症如应激性高血糖、上消化道出血、各种感染等治疗纽耍比对照纽少、或轻、或易控制；治疗组死亡10例，对照纽.11例，两纽死亡例数比较差异无显著性(P>0.05)o结论急性脑出血后在神经细胞转变为不可逆损伤之前尽早应用脑廿肌肽，具有较好的促苏醒作用，减少或减轻因脑出血而引发的各种严重并发症；提高病人的生存质量，降低或减轻致残率；但对死亡率无影响。【关键词】脑昔肌肽;脑出血ClinicaleffectofCerebrosid-Kininforacutece

3、rebndhemorrhageWANGJing-en,CAIJin-fang,WANGZhi-hua,etal.NanhuiCentralHospital,Shanghai201300,China[Abstract]ObjectivesTodiscusstheeffectcerebroside-kinininjectiononprognosisandreversionofneurologicalfunctionofearlyacutecerebralhemorrhage.MethodsAtotalof47patients

4、withacutehypertensivecerebralhemorrhageweredividedintotwogroupsrandomized,23casesweretreatedwithcerebroside-kinininjectionand24caseswerecontrol.AlIthepaientsweretreatedwithsameroutinetherapy.Treatmentgroupwereadministeredbyintravenousinjectiononceadayfor2weekswit

5、hcerebroside-kinininjection20mldilutedwith250ml0.9%salineduringearlyacutecerebralhemorrhage・APACHEIIscoreandGlasgowcomascale(GCS)scorewereusedtoassessimpaireddegree.ResultsTherewasnodifferenceofstateofillnessandcomabetweentwogroupsbeforthetherapy(P>0.05).Therewas

6、significantdifferenceofAPACHEIIandGCSscoreBetweentwogroupsafterthetherapy(P<0.05).Thesmootherstatesofillnessandhigherrecoveryratewereobservedintreatmentgroup(hancontrolgroup・Thecomplicationssuchasstimulated-high-glucoseinblood,thebleedingofupperdigestivetractanda

7、llkindsofinfectionintreatmentgroupwerelessthancontrol.Therewerenosignificantdifferenceofdeathratebetweentwogroups,10casesintreatmentgroupand11casesincontrol(P>0.05).ConclusionAsuccessiveearlyusageofcerebroside-kinininjectionforacutecerebralhemorrhageshowswelleffe

8、ctonrecoveryofcoma,canrelieveallkindscomplicationsinducedbycerebralbycerebralhemorrhageandimproveliveofpatientsandreducethedisabilityandhasnoeffectondeathrate.